Attached files
| file | filename |
|---|---|
| S-1/A - S-1/A - LUMOS PHARMA, INC. | a2201690zs-1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
NewLink Genetics Corporation:
We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.
Our report refers to the adoption of new guidance on the presentation and disclosure of noncontrolling interests.
/s/ KPMG LLP
Des Moines, Iowa
March 18, 2011